The next generation anti-IgE molecule, ligelizumab, a humanized monoclonal IgG1 mAb recognizing an IgE-epitope distinct from that of omalizumab, is also in clinical development for the treatment of allergic disease (Figure 1C). Here, IGHE is linked to allergic disease.